NSG™ Variants Portfolio

NOD.Cg-Prkdc^scidIl2rg^tm1Wjl/SzJ (005557)

NOD.Cg-Prkdc^scidIl2rg^tm1WjlTg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ (013062) 

NOD.Cg-Rag1^tm1MomIl2rg^tm1Wjl/SzJ (007799) 

• Engrafts the widest range of solid and hematological cancers, including ALL and AML
• Most sensitive host for cancer stem cells when compared to NOD scid or nude mice
• Longer lifespan than NOD scid; supports long-term engraftment studies and capabilities; >89 weeks median

• Increased CD4+ FoxP3+ regulatory T cell population after CD34+ humanization
• Enhances human myelopoiesis and terminal differentiation after CD34+ humanization
• Increased efficiency of engrafting human acute myeloid leukemia (AML)

• Long-term multilineage hematopoeitic stem cell repopulation similar to NSG mice
• Engrafts human PBMC without irradiation similar to NSG
• Engrafts a wide range of solid and hematological cancers
• Greater tolerance to genotoxic agents compared to NSG

• No thymic lymphomas, can be used for long & short-term experiments
• Sensitive to irradiation

• Compromised human stem cell regeneration
• Suppression of human erythropoiesis
• Reduction of human B-lymphopoiesis

Ishikawa et al. 2005;
Shultz et al. 2005

Pearson et al. 2008;
Brehm et al. 2010;
Maykel et al. 2014

NOD.Cg-Mcph1^{Tg(HLA-A2.1)1Enge}Prkdc^scidIl2rg^tm1Wjl/SzJ (009617)

NOD.Cg-Prkdc^scid Il2rg^tm1Wjl Tg(HLA-A/H2-D/B2M)1Dvs/SzJ (014570)

NOD.Cg-Tg(HLA-DRA*0101,HLA-DRB1*0101) 1Dmz Prkdc^scid Il2rg^tm1Wjl/GckRolyJ (012479)

NOD.Cg-Prkdc^scid Il2rg^tm1Wjl H2-Ab1^tm1Doi Tg(HLA-DRB1)31Dmz/SzJ (017637)

NOD.Cg-B2m^tm1Unc Prkdc^scid Il2rg^tm1Wjl/SzJ  (010636)

NOD.Cg-Prkdc^scid H2-K1^tm1Bpe H2-D1^tm1Bpe Il2rg^tm1Wjl/SzJ (023848)

HLA Class I-A2 Transgenics
NSG-HLA-A2.1 (009617)
NSG-HLA-A2/HHD (014570)

DR1 (012479)
DR4 (017637)

NSG B2m (010636)
NSG-(K^bD^b)^null (023848)

• High engraftment of HLA-A2-restricted immune cells after CD34+ humanization
• Enable functional CD4+ T cell responses to viral infection after CD34+ humanization (014570)

• Useful for transplantation studies in the absence of xeno-GVHD
• Develop allo-GVHD post-engraftmentof DR4-negative CD4+ T cells (017637)

• Resistant to xeno-GVHD (010636)
• Attenuated xeno-GVHD development post-hPBMC transplantation (023848)
• High hCD45+ cell engraftment (023848)
• Useful for studying mechanisms for xeno-GVHD

• No thymic lymphomas - can be used for long-term experiments
• Sensitive to irradiation 

• Reduced CD45+ cell engraftment compared to NSG
• Higher proportion of mice with no CD45+ cell engraftment as compared to NSG (017637)

• Reduced survival post hCD34+ cell transplantation compared to NSG mice (023848)

NOD.Cg-Prkdc^scid H2-Ab1^em1Mvw H2-K1^tm1BpeH2-D1^tm1Bpe Il2rg^tm1Wjl/SzJ (025216)

NOD.Cg-Prkdc^scid Il2rg^tm1Wjl Tg(IL15)1Sz/SzJ (030890)

NOD.Cg.Kit^W-41JTyr⁺Prkdc^scidIl2rg^tm1Wjl/ThomJ (026622)

MHC I/II KO

IL-15

• Most resistant to xeno-GVHD of all NSG variants
• Extended human IgG half-life compared to B2m knockouts (10636)

• Increased abundance and function of human NK cells following CD34-humanization

• Resistance to xeno-GVHD associated with reduced CD45+ cell expansion in vivo
• Radiation sensitive

• Sensitive to irradiation

NOD.Cg-Prkdc^scidIl2rg^tm1WjlTg(SERPINA1*E342K)#Slcw/SzJ (028842)

NOD.Cg-Tlr4^lps-del Prkdc^scid Il2rg^tm1Wjl/SzJ (033704)

• Engrafts human and allogeneic mouse hepatocytes without rejection 

• Residual mouse innate immune system cannot respond to Tlr4 agonists
• After humanization, NSG-Tlr4 KO are ideal for studying human TLR4-specific responses against tumors

• Shares the same sensitivity to genotoxic agents as other NSG strains

• Shares the same sensitivity to genotoxic agents as other NSG strains